PMID- 31129183
OWN - NLM
STAT- MEDLINE
DCOM- 20190718
LR  - 20190718
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
VI  - 69
DP  - 2019 Jul
TI  - Effects of zinc supplementation on superoxide dismutase activity and gene 
      expression, and metabolic parameters in overweight type 2 diabetes patients: A 
      randomized, double-blind, controlled trial.
PG  - 15-20
LID - S0009-9120(19)30093-1 [pii]
LID - 10.1016/j.clinbiochem.2019.05.008 [doi]
AB  - OBJECTIVE: Despite the current guidelines for the management of type 2 diabetes 
      mellitus (T2DM), patients still struggle with the hyperglycemia consequences. 
      Imbalance in zinc homeostasis, in particular, renders diabetic patients more 
      susceptible to the damages of oxidative stress. This study aimed to evaluate the 
      effects of zinc supplementation on the superoxide dismutase gene expression and 
      enzyme activity in overweight individuals with T2DM. Additionally, biochemical 
      parameters, such as fasting blood glucose (FBG), insulin, glycated hemoglobin 
      (HbA1c), homeostasis model of assessment-insulin resistance (HOMA-IR), serum 
      levels of zinc and lipid profile, were assessed. METHODS: In this randomized, 
      double-blind, placebo-controlled trial, 70 overweight (BMI > 25) T2DM patients 
      were selected based on the inclusion criteria. They were divided into two groups 
      for supplementation of daily 50 mg zinc gluconate or placebo for 8 weeks. Blood 
      samples were collected from all the individuals in the zinc group and controls 
      for analysis. RESULTS: The results showed that, in comparison with the control 
      group, zinc supplementation increased both gene expression and enzyme activity of 
      SOD (p < 0.01) as well as the levels of insulin (p = 0.02) among the patients in 
      the zinc group. Moreover, there was a meaningful reduction in the levels of FBG, 
      HbA1c and HOMA-IR value (p < 0.001), triglycerides and total cholesterol 
      (p < 0.05) after the zinc treatment. CONCLUSIONS: Taken together, the current 
      study suggests that daily supplementation with 50 mg zinc gluconate could be a 
      useful approach for the management of overweight T2DM. CLINICAL TRIAL 
      REGISTRATION: IRCT2015083102.
CI  - Copyright (c) 2019 The Canadian Society of Clinical Chemists. Published by Elsevier 
      Inc. All rights reserved.
FAU - Nazem, Mohammad Reza
AU  - Nazem MR
AD  - Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares 
      University, Tehran, Iran.
FAU - Asadi, Mojgan
AU  - Asadi M
AD  - Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Jabbari, Niloofar
AU  - Jabbari N
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Pharmaceutical Science 
      Branch, Islamic Azad University, Tehran, Iran.
FAU - Allameh, Abdolamir
AU  - Allameh A
AD  - Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares 
      University, Tehran, Iran. Electronic address: allameha@modares.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20190523
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Lipids)
RN  - 0 (Placebos)
RN  - 0 (RNA, Messenger)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - J41CSQ7QDS (Zinc)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/complications/enzymology/genetics/*metabolism
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Overweight/*complications
MH  - Placebos
MH  - RNA, Messenger/metabolism
MH  - Superoxide Dismutase/*genetics/*metabolism
MH  - Zinc/*administration & dosage
OTO - NOTNLM
OT  - Antioxidant therapy
OT  - Overweight
OT  - Superoxide dismutase
OT  - Type 2 diabetes mellitus
OT  - Zinc supplementation
EDAT- 2019/05/28 06:00
MHDA- 2019/07/19 06:00
CRDT- 2019/05/27 06:00
PHST- 2019/01/22 00:00 [received]
PHST- 2019/05/18 00:00 [revised]
PHST- 2019/05/22 00:00 [accepted]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2019/07/19 06:00 [medline]
PHST- 2019/05/27 06:00 [entrez]
AID - S0009-9120(19)30093-1 [pii]
AID - 10.1016/j.clinbiochem.2019.05.008 [doi]
PST - ppublish
SO  - Clin Biochem. 2019 Jul;69:15-20. doi: 10.1016/j.clinbiochem.2019.05.008. Epub 
      2019 May 23.